Vectura Group

Equities

VEC

GB00BKM2MW97

Delayed London S.E. Other stock markets 11:35:22 2021-10-18 am EDT			5-day change	1st Jan Change
164.8 ^GBX	-.--%		-.--%	-.--%

Apr. 16	Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	CI
2021	EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	CI

Vectura at CPhI North America 2021: July 26 – August 6 Published26/07/2021 Read more

July 26, 2021 at 05:38 am EDT

Published:26/07/2021

Join us (virtually) at CPhI North America 2021: July 26 - August 6, 2021, an event that will gather thousands of pharma professionals productive days of networking, sourcing, and learning.

Robert Gurley, Russell Miller and Bas Hoffmann from our expert team will be happy to discuss your inhaled development requirements.

In the CPHI Learning Lab series, Geraldine Venthoye, Vectura's Chief Scientific Officer, presents 'Take a Breath: Selecting the Right Delivery Platform for Inhaled Product Development', where she discusses the factors affecting platform selection from early development to commercialisation, as well as strategies to accelerate an inhaled development programme.

Attachments

Original document
Permalink

Disclaimer

Vectura Group plc published this content on 26 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2021 09:37:07 UTC.

Latest news about Vectura Group

Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	Apr. 16	CI
EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	21-12-28	CI
Philip Morris CEO does not need M&A to hit smoke free goals	21-12-03	RE
Philip Morris International : Raises Lobbying Concerns Over $1.4 Billion Vectura Deal	21-10-25	MT
PMI Global Services, Inc Completes the Acquisition of Vectura Group plc	21-10-19	CI
Vectura Group plc's Equity Buyback announced on September 10, 2019, has expired.	21-10-18	CI
PMI Global Services, Inc. completed the acquisition of Vectura Group plc from AXA Investment Managers S.A., Legal & General Investment Management Limited, The Vanguard Group, Inc. and others.	21-10-18	CI
Vectura Group plc(LSE:VEC) dropped from S&P Global BMI Index	21-10-08	CI
Philip Morris International : Extends Offer Period For Vectura Takeover	21-10-01	MT
Morrisons takeover battle will go to UK auction on Oct. 2	21-09-29	RE
Vectura Group plc(LSE:VEC) dropped from FTSE 250 Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE 250 (Ex Investment Companies) Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE 350 (Ex Investment Companies) Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE 350 Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE All-Share Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE techMARK All-Share Index	21-09-21	CI
Philip Morris International : to Delist Britain's Vectura on Oct. 19	21-09-20	MT
Vectura : Pharmaceutical Conference Bans Vectura After Takeover By Philip Morris	21-09-20	MT
Augean : Buyout battle for waste management firm Augean headed to auction - regulator	21-09-16	RE
Today on Wall Street: US economy shows resilience, while China falters	21-09-16
Philip Morris seals deal for UK's Vectura despite health group concerns	21-09-16	RE
FTSE Rises, Ashtead Gains After 1Q Profit Boost, Guidance Increase	21-09-16	DJ
Philip Morris Confirms Majority of Vectura Shareholders Agree to Takeover	21-09-16	CI
Philip Morris International : Secures Vectura Takeover with 75% support	21-09-16	MT
BOE Expected to Leave Policy Unchanged Next Week	21-09-16	DJ

Chart Vectura Group

Duration

Period

More charts

Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Sector

More about the company